View in EDS PDF Full Text

A Phase I Trial of Alpelisib Combined With Capecitabine in Patients With HER2-Negative Metastatic Breast Cancer.

Saved in:
Bibliographic Details
Title: A Phase I Trial of Alpelisib Combined With Capecitabine in Patients With HER2-Negative Metastatic Breast Cancer.
Authors: File DM; Department of Medical Oncology, The University of North Carolina at Chapel Hill, Chapel Hill, NC., Abdou Y; Department of Medical Oncology, The University of North Carolina at Chapel Hill, Chapel Hill, NC; Lineberger Comprehensive Cancer Center, Chapel Hill, NC. Electronic address: Yara_Abdou@med.unc.edu., Force J; Department of Medicine, Duke University, Durham, NC; Duke Cancer Institute, Durham, NC., Moore DT; Lineberger Comprehensive Cancer Center, Chapel Hill, NC., Anders CK; Department of Medicine, Duke University, Durham, NC; Duke Cancer Institute, Durham, NC., Reeder-Hayes K; Department of Medical Oncology, The University of North Carolina at Chapel Hill, Chapel Hill, NC; Lineberger Comprehensive Cancer Center, Chapel Hill, NC., Carey LA; Department of Medical Oncology, The University of North Carolina at Chapel Hill, Chapel Hill, NC; Lineberger Comprehensive Cancer Center, Chapel Hill, NC., Muss HB; Department of Medical Oncology, The University of North Carolina at Chapel Hill, Chapel Hill, NC; Lineberger Comprehensive Cancer Center, Chapel Hill, NC., Perou CM; Department of Medical Oncology, The University of North Carolina at Chapel Hill, Chapel Hill, NC; Lineberger Comprehensive Cancer Center, Chapel Hill, NC; Department of Genetics, The University of North Carolina, Chapel Hill, NC., Marcom PK; Department of Medicine, Duke University, Durham, NC; Duke Cancer Institute, Durham, NC., Dees EC; Department of Medical Oncology, The University of North Carolina at Chapel Hill, Chapel Hill, NC; Lineberger Comprehensive Cancer Center, Chapel Hill, NC.
Source: Clinical breast cancer [Clin Breast Cancer] 2024 Dec; Vol. 24 (8), pp. 683-690. Date of Electronic Publication: 2024 Aug 08.
Publication Type: Journal Article; Clinical Trial, Phase I
Journal Info: Publisher: Elsevier Country of Publication: United States NLM ID: 100898731 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1938-0666 (Electronic) Linking ISSN: 15268209 NLM ISO Abbreviation: Clin Breast Cancer Subsets: MEDLINE
Database: MEDLINE Ultimate
FullText Links:
  – Type: pdflink
Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 39217059
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: A Phase I Trial of Alpelisib Combined With Capecitabine in Patients With HER2-Negative Metastatic Breast Cancer.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22File+DM%22">File DM</searchLink>; Department of Medical Oncology, The University of North Carolina at Chapel Hill, Chapel Hill, NC.<br /><searchLink fieldCode="AU" term="%22Abdou+Y%22">Abdou Y</searchLink>; Department of Medical Oncology, The University of North Carolina at Chapel Hill, Chapel Hill, NC; Lineberger Comprehensive Cancer Center, Chapel Hill, NC. Electronic address: Yara_Abdou@med.unc.edu.<br /><searchLink fieldCode="AU" term="%22Force+J%22">Force J</searchLink>; Department of Medicine, Duke University, Durham, NC; Duke Cancer Institute, Durham, NC.<br /><searchLink fieldCode="AU" term="%22Moore+DT%22">Moore DT</searchLink>; Lineberger Comprehensive Cancer Center, Chapel Hill, NC.<br /><searchLink fieldCode="AU" term="%22Anders+CK%22">Anders CK</searchLink>; Department of Medicine, Duke University, Durham, NC; Duke Cancer Institute, Durham, NC.<br /><searchLink fieldCode="AU" term="%22Reeder-Hayes+K%22">Reeder-Hayes K</searchLink>; Department of Medical Oncology, The University of North Carolina at Chapel Hill, Chapel Hill, NC; Lineberger Comprehensive Cancer Center, Chapel Hill, NC.<br /><searchLink fieldCode="AU" term="%22Carey+LA%22">Carey LA</searchLink>; Department of Medical Oncology, The University of North Carolina at Chapel Hill, Chapel Hill, NC; Lineberger Comprehensive Cancer Center, Chapel Hill, NC.<br /><searchLink fieldCode="AU" term="%22Muss+HB%22">Muss HB</searchLink>; Department of Medical Oncology, The University of North Carolina at Chapel Hill, Chapel Hill, NC; Lineberger Comprehensive Cancer Center, Chapel Hill, NC.<br /><searchLink fieldCode="AU" term="%22Perou+CM%22">Perou CM</searchLink>; Department of Medical Oncology, The University of North Carolina at Chapel Hill, Chapel Hill, NC; Lineberger Comprehensive Cancer Center, Chapel Hill, NC; Department of Genetics, The University of North Carolina, Chapel Hill, NC.<br /><searchLink fieldCode="AU" term="%22Marcom+PK%22">Marcom PK</searchLink>; Department of Medicine, Duke University, Durham, NC; Duke Cancer Institute, Durham, NC.<br /><searchLink fieldCode="AU" term="%22Dees+EC%22">Dees EC</searchLink>; Department of Medical Oncology, The University of North Carolina at Chapel Hill, Chapel Hill, NC; Lineberger Comprehensive Cancer Center, Chapel Hill, NC.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22100898731%22">Clinical breast cancer</searchLink> [Clin Breast Cancer] 2024 Dec; Vol. 24 (8), pp. 683-690. <i>Date of Electronic Publication: </i>2024 Aug 08.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article; Clinical Trial, Phase I
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Elsevier%22">Elsevier </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>100898731 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1938-0666 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2215268209%22">15268209 </searchLink><i>NLM ISO Abbreviation: </i>Clin Breast Cancer <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=39217059
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1016/j.clbc.2024.08.001
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 683
    Titles:
      – TitleFull: A Phase I Trial of Alpelisib Combined With Capecitabine in Patients With HER2-Negative Metastatic Breast Cancer.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: File DM
      – PersonEntity:
          Name:
            NameFull: Abdou Y
      – PersonEntity:
          Name:
            NameFull: Force J
      – PersonEntity:
          Name:
            NameFull: Moore DT
      – PersonEntity:
          Name:
            NameFull: Anders CK
      – PersonEntity:
          Name:
            NameFull: Reeder-Hayes K
      – PersonEntity:
          Name:
            NameFull: Carey LA
      – PersonEntity:
          Name:
            NameFull: Muss HB
      – PersonEntity:
          Name:
            NameFull: Perou CM
      – PersonEntity:
          Name:
            NameFull: Marcom PK
      – PersonEntity:
          Name:
            NameFull: Dees EC
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 12
              Text: 2024 Dec
              Type: published
              Y: 2024
          Identifiers:
            – Type: issn-electronic
              Value: 1938-0666
          Numbering:
            – Type: volume
              Value: 24
            – Type: issue
              Value: 8
          Titles:
            – TitleFull: Clinical breast cancer
              Type: main
ResultId 1